The Pfizer and Novo Nordisk battle for obesity drug developer Metsera intensified on Thursday after a fresh round of ...

The revised bids are the latest unusual twist in the fight between big drugmakers over drug developer Metsera.

Pfizer Inc. ( PFE) Discusses Clinical Development Strategy for 4404 Bispecific Antibody in Oncology November 10, 2025 8:30 AM EST ...

At the end of September, President Trump invited Pfizer CEO Albert Bourla to the Oval Office to announce that the company and the administration had reached a "deal" on most-favoured nations drug ...

Eli Lilly and Novo are preparing to announce new drug pricing deals with the White House, including for their blockbuster weight loss drugs. Blackstone Life Sciences will pay Merck $700 million for ...

Revised transaction values Metsera at up to $86.25 per share -- Metsera's Board of Directors unanimously recommends that Metsera stockholders approve the adoption of the amended Pfizer merger ...

Alberto Espay was not prepared for how his world would be upended when he published a study on the number of people who have died while taking new, high-profile Alzheimer’s drugs. Last October, the ...

Pfizer and Novo Nordisk seem to want Metsera bad. Analysts are wondering, though: is the obesity biotech really worth this much effort?

Pfizer Inc. (NYSE: PFE) today issued the following statement in response to the Delaware Chancery Court's decision denying Pfizer's request for a temporary restraining order to prevent Metsera, Inc.

Pfizer Inc. today announced that it has filed a lawsuit against Metsera, Inc., its Board of Directors, and Novo Nordisk, S.A. in the Delaware Court of ...

Portfolio Receipts growth of 11% to $814 million; Royalty Receipts growth of 11% Net cash provided by operating activities of $703 million Raised ...